2014

YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012

MISSISSAUGA, ON, May 11, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology and cancer related products, today reported operational and financial results for its third quarter of fiscal 2012, ended March 31, 2012.

"In the past few months we delivered robust Phase I/II results for our JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis and we raised an additional $80 million principally to support the further advancement of this drug," said Dr. Nick Glover, President and CEO of YM BioSciences. "Our current focus is on confirming our Phase III clinical strategy for CYT387 with both North American and European regulators with the expectation that, subject to these regulatory discussions, we will begin enrolling patients in pivotal trials in the second half of calendar 2012."

CYT387 Next Steps:

  • Subject to regulatory clearance, pivotal trials for CYT387 in myelofibrosis are targeted to begin in the second half of calendar 2012.
  • Final nine-month data from the ongoing 166-patient Phase I/II Core trial are expected to be reported by the end of calendar 2012.
  • Interim data from the Phase I/II Extension trial, in which patients who have completed the Core trial are able to continue long-term treatment with CYT387, are expected to be reported by the end of calendar 2012.
  • Interim data from the BID (twice-daily dosing) Phase II trial of CYT387 are expected to be reported by the end of calendar 2012.
  • YM may evaluate CYT387's effectiveness in additional clinical indications and is currently in the process of designing clinical trials for these indications.
  • YM will entertain strategic discussions with other companies for the next stages of development for CYT387 and will weigh any opportunities against the prospect of retaining full commercial economics by advancing CYT387 further into pivotal trials on its own.

Financial Results (CDN dollars)
The interim consolidated financial statements and comparative information for the third quarter of fiscal 2012 have been prepared in accordance with International Financial Reporting Standards ("IFRS"). Previously, up to June 30, 2011, the Company prepared its Interim and Annual Consolidated Financial Statements in accordance with Canadian Generally Accepted Accounting Principles ("Canadian GAAP").

Revenue, primarily from out-licensing, for the third quarter of fiscal 2012 ended March 31, 2012, was $0.1 million compared with $0.2 million for the third quarter of fiscal 2011. Revenue from out-licensing for the first nine months of fiscal 2012 was $0.7 million compared with $0.8 million for the first nine months of fiscal 2011. The decreases were due to a two-year increase in the period over which the deferred revenue is being recognized.

Net finance income was $0.3 million for the third quarter of fiscal 2012 compared to net finance costs of $1.5 million for the third quarter of fiscal 2011. Net finance income was $9.3 million for the first nine months of fiscal 2012 compared to net finance costs of $9.8 million for the first nine months of fiscal 2011. The changes in net finance income are primarily attributable to changes in the fair value adjustment for USD warrants. Under IFRS, warrants denominated in a different currency than the Company's functional currency must be classified as a financial liability and measured at fair value, with changes reflected in profit or loss. For the third quarter of fiscal 2012, the Company incurred a loss of $0.4 million on the revaluation of warrants, compared to a loss of $1.1 million for the third quarter of fiscal 2011. For the first nine months of fiscal 2012, the Company incurred a gain of $6.8 million on the revaluation of warrants, compared to a loss of $8.6 million for the first nine months of fiscal 2011.

Licensing and product development expenses were $5.8 million for the third quarter of fiscal 2012 compared with $5.5 million for the third quarter of fiscal 2011. Licensing and product development expenses were $19.5 million for the first nine months of fiscal 2012 compared with $16.4 million for the first nine months of fiscal 2011. For the third quarter of fiscal 2012, core expenses for licensing and product development remained constant at $3.0 million compared to the three months ended March 31, 2011, costs associated with development activities for CYT387 increased by $1.0 million to $2.5 million, and costs associated with development activities for nimotuzumab decreased by $0.7 million to $0.2 million. Development expenses for CYT387 increased due to the expansion of the Phase I/II clinical trial in myelofibrosis, start-up costs associated with the BID (twice-daily dosing) study, pre-clinical development activities, and manufacturing of drug for these programs.

General and administrative expenses were $1.4 million for the third quarter of fiscal 2012 compared to $1.6 million for the third quarter of fiscal 2011. General and administrative expenses were $4.7 million for the first nine months of fiscal 2012 compared to $6.6 million for the first nine months of fiscal 2011, primarily due to severance and restructuring costs incurred in fiscal 2011.

Net loss for the third quarter of fiscal 2012 was $6.8 million ($0.05 per share) compared to $8.3 million ($0.08 per share) for the same period last fiscal year. Net loss for the first nine months of fiscal 2012 was $14.2 million ($0.12 per share) compared to $32.0 million ($0.35 per share) for the same period last fiscal year. Under IFRS, net loss has been volatile, caused by the requirement to adjust the carrying value of liabilities such as USD warrants and stock appreciation rights to fair value at each measurement date, with changes being reflected in net loss for the quarter.

During the third quarter of fiscal 2012, the Company completed a prospectus offering of 40,250,000 shares for gross proceeds of $79.4 million (U.S. $80.5 million) resulting in a net cash proceeds of $74.2 million.

As at March 31, 2012 the Company had cash and short-term deposits totaling $137.2 million and accounts payables and accrued liabilities totaling $3.1 million compared to $79.7 million and $4.4 million respectively at June 30, 2011.

As at March 31, 2012 the Company had 157,402,353 common shares and 7,366,418 warrants outstanding.

About YM BioSciences
YM BioSciences Inc. is a drug development company primarily focused on advancing CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. Positive interim results have been reported from a Phase I/II trial of CYT387 in 166 patients with myelofibrosis. This trial has completed enrollment while a 60 patient Phase II twice-daily dose escalation trial is currently recruiting patients. YM's portfolio also includes nimotuzumab, a humanized monoclonal antibody targeting EGFR with an enhanced side-effect profile over currently marketed EGFR-targeting antibodies. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and has completed a Phase II trial in glioblastoma multiforme. In addition to YM's three products, the Company has several preclinical research programs underway with candidates from its library of novel compounds identified through internal research conducted at YM BioSciences Australia.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that CYT387, nimotuzumab and CYT997 will generate positive efficacy and safety data in ongoing and future clinical trials, and that YM and its various licensees will complete their respective clinical trials and disclose data within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

               
               
               
YM BIOSCIENCES INC.              
Condensed Consolidated Interim Statements of Financial Position            
(Expressed in Canadian dollars, unless otherwise noted)            
(Unaudited)                
                 
    March 31,
2012
      June 30,
2011
  July 1,
2010
                 
Assets                
Current assets:                
  Cash and cash equivalents $ 90,830,767     $ 32,046,630    $ 19,460,141
  Short-term deposits   46,362,847       47,611,922   26,184,991
  Accounts receivable   248,738       205,900   161,184
  Prepaid expenses   428,114       731,676   237,962
  Total current assets   137,870,466       80,596,128   46,044,278
                 
Non-current assets:                
  Property and equipment   62,157       91,320   84,775
  Intangible assets   3,756,686       7,137,698   11,645,714
  Total non-current assets   3,818,843       7,229,018   11,730,489
                 
Total assets $ 141,689,309     $ 87,825,146 $ 57,774,767
                 
Liabilities and Equity                
Current liabilities:                
  Accounts payable $ 1,287,062     $ 1,718,893 $ 699,277
  Accrued liabilities   1,783,598       2,652,511   2,085,824
  Share purchase warrants   7,630,176       14,476,681   6,358,480
  Deferred revenue   381,270       594,072   1,523,916
  Total current liabilities   11,082,106       19,442,157   10,667,497
                 
Non-current liabilities:                
  Deferred revenue   1,652,170       1,831,722   1,650,909
  Total non-current liabilities   1,652,170       1,831,722   1,650,909
                 
Equity:                
  Share capital   339,867,098       264,548,643   203,498,239
  Contributed surplus   16,478,999       15,144,062   14,232,353
  Deficit   (227,391,064)       (213,141,438)   (172,274,231)
  Total equity   128,955,033       66,551,267   45,456,361
                 
Total liabilities and equity $ 141,689,309     $ 87,825,146 $ 57,774,767
                 
                 
Approved by the Board and authorized for issue on May 10, 2012:            
                 
"Tryon Williams" Director              
                 
"David G.P. Allan" Director              
                 
                 
                 
YM BIOSCIENCES INC.                  
Condensed Consolidated Interim Statements of Comprehensive Income          
(Expressed in Canadian dollars, unless otherwise noted)              
(Unaudited)                  
                   
        Three months
ended March 31,
Nine months
ended March 31,
    2012     2011   2012   2011
                   
Revenue:                  
  Out-licensing $ 109,107   $ 217,489      $ 739,952      $ 811,262
                   
Expenses:                  
  Licensing and product development   5,755,426     5,493,790   19,503,754   16,432,545
  General and administrative   1,433,113     1,606,297   4,748,144   6,560,907
    7,188,539     7,100,087   24,251,898   22,993,452
                   
Loss before the undernoted   (7,079,432)     (6,882,598)   (23,511,946)   (22,182,190)
                   
Finance income   699,990     170,437   9,262,320   319,935
Finance costs   (417,716)     (1,642,363)   -   (10,140,698)
Other income   -     9,528   -   34,444
                   
                   
Net loss for the period and
 comprehensive loss
$ (6,797,158)   $ (8,344,996) $ (14,249,626) $ (31,968,509)
                   
Basic and diluted loss per common share $ (0.05)   $ (0.08) $ (0.12) $ (0.35)
                   
                   
                   
YM BIOSCIENCES INC.              
Condensed Consolidated Interim Statements of Changes in Equity        
(Expressed in Canadian dollars, unless otherwise noted)            
(Unaudited)                  
                   
  Share capital   Contributed        
  Number   Amount   surplus   Deficit   Total
                   
                   
Balance, June 30, 2011 116,681,948 $ 264,548,643 $ 15,144,062 $ (213,141,438) $ 66,551,267
                   
Net loss for the period -   -   -   (14,249,626)   (14,249,626)
                   
Transactions with owners of the Company,
  recognized directly in equity:
                                                     
    Shares issued pursuant to prospectus offering   40,250,000       74,232,207       -       -       74,232,207
  Share-based compensation -   -   1,880,899   -   1,880,899
  Shares issued on exercise of options   470,405       1,086,248       (545,962)       -       540,286
  Total transactions with owners of the Company   40,720,405       75,318,455       1,334,937       -       76,653,392
                   
Balance, March 31, 2012 157,402,353 $ 339,867,098 $ 16,478,999 $ (227,391,064) $ 128,955,033
                   
                   
                   
  Share capital   Contributed        
  Number   Amount   surplus   Deficit   Total
                   
                   
Balance, July 1, 2010 80,359,623 $ 203,498,239 $ 14,232,353 $ (172,274,231) $ 45,456,361
                   
Net loss for the period -   -   -   (31,968,509)   (31,968,509)
                   
Transactions with owners of the Company,
  recognized directly in equity:
                                                     
  Share-based compensation -   -   1,436,442   -   1,436,442
  Shares issued on exercise of options   824,160       1,427,213       (576,909)       -       850,304
  Shares issued on exercise of warrants   660,529       2,131,506       -       -       2,131,506
  Shares issued pursuant to prospectus offering   29,250,000       44,499,915       -       -       44,499,915
  Total transactions with owners of the Company   30,734,689       48,058,634       859,533       -       48,918,167
                   
Balance, March 31, 2011 111,094,312 $ 251,556,873 $ 15,091,886 $ (204,242,740) $ 62,406,019
                   
                   
                   
YM BIOSCIENCES INC.                
Condensed Consolidated Interim Statements of Cash Flows            
(Expressed in Canadian dollars, unless otherwise noted)            
(Unaudited)                
                 
    Three months
ended March 31,
  Nine months
ended March 31,
    2012   2011   2012   2011
                 
Cash provided by (used in):                
                 
Operating activities:                
  Net loss for the period $ (6,797,158) $ (8,344,996) $ (14,249,626) $ (31,968,509)
  Items not involving cash:                
      Depreciation of property and equipment  
 
 
12,521
 
 
 
20,598
 
 
 
45,655
 
 
 
59,745
      Amortization of intangible assets   1,127,004   1,127,004   3,381,012   3,381,012
      Interest earned   (178,400)   (170,437)   (487,568)   (308,812)
      Unrealized (gain) loss on cash and cash equivalents  
 
 
506,775
 
 
 
505,016
 
 
 
(899,883)
 
 
 
1,515,378
      Gain on disposal of property and equipment  
 
 
-
 
 
 
-
 
 
 
-
 
 
 
(10,744)
      Share-based compensation   373,215   392,244   1,880,899   1,436,442
      Change in fair value of share purchase warrants  
 
 
417,716
 
 
 
1,137,347
 
 
 
(6,846,505)
 
 
 
8,625,320
  Changes in non-cash working capital balances:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Short-term deposits   (144,981)   (156,223)   (450,258)   (262,590)
      Accounts receivable   35,697   (91,833)   (42,838)   (133,812)
      Prepaid expenses   63,498   104,128   303,562   (152,588)
      Accounts payable   (249,939)   (437,564)   (431,831)   275,121
      Accrued liabilities   (386,440)   (809,927)   (868,913)   718,958
      Deferred revenue   (95,318)   (148,518)   (392,354)   (600,513)
  Net cash used in operating activities   (5,315,810)   (6,873,161)   (19,058,648)   (17,425,592)
                 
Investing activities:                
  Proceeds from sale of short-term deposits   12,192,896   13,721,647   47,999,333   62,575,864
  Purchase of short-term deposits   (12,000,000)   (12,500,000)   (46,300,000)   (88,514,540)
  Interest received   178,400   170,437   487,568   308,812
  Additions to property and equipment   (6,272)   (16,267)   (16,492)   (68,961)
  Net cash provided by (used in) investing activities    365,024    1,375,817    2,170,409    (25,698,825)
                   
                 
Financing activities:                
  Issuance of common shares on exercise of options    517,836    596,495    540,286    850,304
                   
  Issue of common shares on exercise warrants    -    135,058    -    985,217
                   
  Net proceeds from issuance of shares   74,232,207   1,165,392   74,232,207   44,499,914
  Net cash provided by financing activities   74,750,043   1,896,945   74,772,493   46,335,435
                 
Impact of foreign exchange rates on cash   (506,775)   (505,016)   899,883   (1,515,378)
                 
Increase (decrease) in cash and cash equivalents   69,292,482   (4,105,415)   58,784,137   1,695,640
                 
Cash and cash equivalents, beginning of period   21,538,285   25,261,196   32,046,630   19,460,141
                 
Cash and cash equivalents, end of period $ 90,830,767 $ 21,155,781 $ 90,830,767 $ 21,155,781

 

 

 

 

SOURCE YM BioSciences Inc.




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.